HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Successful double peripheral blood stem cell transplantation for patient with malignant lymphoma of primary induction failure].

Abstract
Three patients with non-Hodgkin's lymphoma of intermediate-grade histologies, who had failed to achieve a complete remission (CR) after more than several courses of conventional chemotherapy were treated with two cycles of high-dose chemotherapy with autologous peripheral blood stem cell transplantation (double PBSCT). All patients received regimen A with carboplatin 1g/m2, etoposide 1.2g/m2 and cyclophosphamide 120mg/kg prior to 1st PBSCT and obtained a partial remission. One patients received regimen A and two patients received regimen B with MCNU 500mg/m2, etoposide 750mg/m2 and L-PAM 140mg/m2 prior to 2nd PBSCT and all patients obtained CR. Second PBSCT was performed 3 to 5 months after the 1st PBSCT. At a median follow-up of 36 (range; 29 to 54) months, all patients remained in continuous CR. The period after reinfusion of PBSCT to achieve a neutrophil count more than 500/microliters ranged between 7 and 9 days and to achieve a platelet count more than 5 x 10(4)/microliters ranged 12 and 22 days. Grade 3 nonhematologic toxicity (mucositis) was seen in one patient after 2nd PBSCT. Double PBSCT could be well tolerated with a high response rate in patients with malignant lymphoma of primary induction failure.
AuthorsH Fujii, H Nakagawa, M Nakao, Y Sonoda, S Tanimukai
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 39 Issue 5 Pg. 369-73 (May 1998) ISSN: 0485-1439 [Print] Japan
PMID9637887 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Granulocyte Colony-Stimulating Factor
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Blood Cell Count
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Granulocyte Colony-Stimulating Factor (administration & dosage)
  • Hematopoiesis
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Lymphoma, Non-Hodgkin (blood, therapy)
  • Male
  • Middle Aged
  • Remission Induction
  • Time Factors
  • Treatment Failure
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: